PMID- 34246191
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20211216
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 141
DP  - 2021 Sep
TI  - Suppression of plasmacytoid dendritic cell migration to colonic isolated lymphoid 
      follicles abrogates the development of colitis.
PG  - 111881
LID - S0753-3322(21)00663-6 [pii]
LID - 10.1016/j.biopha.2021.111881 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) play a pivotal role in maintaining 
      immunological homeostasis by orchestrating innate and adaptive immune responses 
      via migration to inflamed sites and the lymph nodes (LNs). Plasmacytoid DCs 
      (pDCs) have been reported to accumulate in the colon of inflammatory bowel 
      disease (IBD) patients and dextran sulfate sodium (DSS)-induced colitis mice. 
      However, the role of pDCs in the progression of colonic inflammation remains 
      unclear. METHODS: 80 compounds in natural medicines were searched for inhibitors 
      of pDC migration using bone marrow-derived pDCs (BMpDCs) and conventional DCs 
      (BMcDCs). BALB/c mice were given 3% DSS in the drinking water to induce acute 
      colitis. Compounds, which specifically inhibited pDC migration, were 
      administrated into DSS-induced colitis mice. FINDINGS: Astragaloside IV (As-IV) 
      and oxymatrine (Oxy) suppressed BMpDC migration but not BMcDC migration. In 
      DSS-induced colitis mice, the number of pDCs was markedly increased in the 
      colonic lamina propria (LP), and the expression of CCL21 was obviously observed 
      in colonic isolated lymphoid follicles (ILFs). As-IV and Oxy reduced symptoms of 
      colitis and the accumulation of pDCs in colonic ILFs but not in the colonic LP. 
      Moreover, in a BMpDC adoptive transfer model, BMpDC migration to colonic ILFs was 
      significantly decreased by treatment with As-IV or Oxy. INTERPRETATION: pDCs 
      accumulated in the colon of colitis mice, and As-IV and Oxy ameliorated colitis 
      by suppressing pDC migration to colonic ILFs. Accordingly, the selective 
      inhibition of pDC migration may be a potential therapeutic approach for treating 
      colonic inflammatory diseases.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, Japan.
FAU - Yamamoto, Takeshi
AU  - Yamamoto T
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, Japan. Electronic address: ty@inm.u-toyama.ac.jp.
FAU - Hayashi, Shusaku
AU  - Hayashi S
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, Japan.
FAU - Kadowaki, Makoto
AU  - Kadowaki M
AD  - Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, 
      University of Toyama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210707
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Alkaloids)
RN  - 0 (Quinolizines)
RN  - 0 (Saponins)
RN  - 0 (Triterpenes)
RN  - 3A592W8XKE (astragaloside A)
RN  - 85U4C366QS (oxymatrine)
RN  - 9042-14-2 (Dextran Sulfate)
SB  - IM
MH  - Alkaloids/pharmacology/therapeutic use
MH  - Animals
MH  - Cell Movement/*drug effects/physiology
MH  - Colitis/chemically induced/pathology/*prevention & control
MH  - Colon/*drug effects/pathology
MH  - Dendritic Cells/*drug effects/pathology
MH  - Dextran Sulfate/toxicity
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Quinolizines/pharmacology/therapeutic use
MH  - Saponins/pharmacology/therapeutic use
MH  - Tertiary Lymphoid Structures/chemically induced/pathology/*prevention & control
MH  - Triterpenes/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Cell migration
OT  - Colitis
OT  - Isolated lymphoid follicles
OT  - Plasmacytoid dendritic cell
EDAT- 2021/07/11 06:00
MHDA- 2021/12/17 06:00
CRDT- 2021/07/10 20:27
PHST- 2021/03/25 00:00 [received]
PHST- 2021/06/23 00:00 [revised]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/11 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2021/07/10 20:27 [entrez]
AID - S0753-3322(21)00663-6 [pii]
AID - 10.1016/j.biopha.2021.111881 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2021 Sep;141:111881. doi: 10.1016/j.biopha.2021.111881. Epub 
      2021 Jul 7.